EngineeredSyntheticPhageTherapies

Why It Matters

This technology directly addresses the global crisis of antibiotic resistance, which is projected to cause 10 million deaths annually by 2050 and inflict a cumulative $100 trillion economic burden. Imagine a future where a personalized 'phage cocktail' can precisely eliminate a life-threatening bacterial infection, even those resistant to all known antibiotics, saving countless lives. Patients with untreatable infections and specialized biotechnology companies would be major beneficiaries, while traditional antibiotic manufacturers might face market disruption. Technical barriers include developing broad-spectrum but specific phage cocktails, ensuring rapid diagnostics for phage susceptibility, and overcoming regulatory hurdles for genetically modified organisms. We might see initial FDA approvals for specific applications within 5-10 years, with wider adoption in 10-20 years. The US, UK, Belgium, and Georgia (where phage therapy has a longer history) are key players. A second-order consequence could be the emergence of 'phage resistance' in bacteria, leading to an arms race requiring continuous engineering of new phages.